Oyster Point Pharma announces varenicline solution nasal spray for treatment of dry eye to be covered by key Medicare pharmacy benefit managerAugust 17th 2022
Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.
FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indicationsAugust 3rd 2022
Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.
Children’s mental health and the impact of vision impairmentAugust 2nd 2022
Two studies conducted in collaboration with Orbis International explore how providing free glasses to children improves their ability to learn in school and that addressing visual impairment in children can alleviate depression and anxiety.
Clearside Biomedical completes dosing in OASIS Phase 1/2a clinical trial of CLS-AXJuly 26th 2022
According to the company, the study assesses the safety and tolerability of a single dose of CLS-AX administered to patients diagnosed with wet AMD by suprachoroidal injection.
Nanoscope Therapeutics announces first patient dosed in STARLIGHT Phase 2 clinical trial of MCO-010 optogenetic gene therapy for Stargardt diseaseJuly 25th 2022
According to the company, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.
Belite Bio submits IND application to FDA for approval to proceed with LBS-008 Phase 3 clinical trialJuly 22nd 2022
LBS-008 is the company’s orally administered tablet for the treatment of Stargardt disease. There are currently no FDA approved treatments for Stargardt disease or dry AMD.
How to inhibit photoreceptor death? A new way to fight pigmentary retinopathyJuly 21st 2022
A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research in Poland, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.
Carl Zeiss Meditec, Precise Bio announce partnership in the development and commercialization of tissue-based implants for ophthalmologyJuly 20th 2022
The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants.